Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. To investigate the efficacy of afatinib treatment...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: Ishii, Hidenobu, Azuma, Koichi, Sakai, Kazuko, Naito, Yoshiko, Matsuo, Norikazu, Tokito, Takaaki, Yamada, Kazuhiko, Hoshino, Tomoaki, Nishio, Kazuto
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971280/
https://ncbi.nlm.nih.gov/pubmed/31959859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-57624-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares